Personalized Pemafibrate Dosing Systems

The present invention relates to a next-generation pemafibrate dosing system that leverages machine learning, wearable devices, and targeted delivery to optimize treatment outcomes and minimize adverse effects.

The original patent disclosed pemafibrate dosing regimens, but these regimens have limitations in terms of individual patient variability and response to OATP1B inhibitors. The present inventive concept addresses these limitations by introducing personalized and adaptive dosing approaches that account for genetic profiles, dynamic responses, and liver-specific biomarkers.

The inventive concept comprises a system for personalized pemafibrate dosing, utilizing a database of patient genetic profiles and a machine learning algorithm to predict optimal dosing regimens. Additionally, the system includes methods for adaptive pemafibrate dosing, wherein the dosage is adjusted in real-time based on a patient's dynamic response to OATP1B inhibitors, as monitored by a wearable device or mobile application. Furthermore, the inventive concept encompasses pemafibrate formulations for targeted delivery to the liver, comprising nanoparticle or liposome carriers that selectively release the active compound in response to liver-specific biomarkers.

The new claims introduce a paradigm shift in pemafibrate dosing by incorporating machine learning, wearable devices, and targeted delivery. These innovations are non-obvious and novel compared to the original patent, which focused on fixed dosing regimens.

Alternative embodiments of the inventive concept may include the use of different machine learning algorithms, wearable devices, or targeted delivery mechanisms. Variations may also include the integration of additional data sources, such as electronic health records or genomic data, to further personalize pemafibrate dosing.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of dyslipidemia and related cardiovascular diseases. The targeted delivery and adaptive dosing approaches may also have applications in other therapeutic areas, such as oncology and immunology.